Pfizer & BioNTech Receives MHRA's EUA for BNT162b2 Against COVID-19
Shots:
- Pfizer & BioNTech reports that the MHRA in the UK has granted a temporary authorization for the EU for BNT162b2 against COVID-19. The distribution of vaccine will be prioritized according to the populations identified in guidance from the JCVI
- The MHRA’s decision is based on a rolling submission- including data from the P-III study- demonstrating 95% efficacy in participants without & with/ out prior SARS-CoV-2 infection- in each case measured from 7 days after the second dose
- This marks the first EUA following a WW P-III trial of a vaccine to combat the pandemic. The companies are anticipating further regulatory decisions across the globe in Dec’2020
Ref: Pfizer | Image: The Jakarta Post
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com